Abdus Sabur
Overview
Explore the profile of Abdus Sabur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabur A, Khan A, Borphukan B, Razzak A, Salimullah M, Khatun M
J Xenobiot
. 2025 Feb;
15(1).
PMID: 39997362
The lack of new antibacterial medicines and the rapid rise in bacterial resistance to antibiotics pose a major threat to individuals and healthcare systems. Despite the availability of various antibiotics,...
2.
Das A, Asad M, Sabur A, Didwania N, Ali N
ACS Appl Bio Mater
. 2022 Jan;
1(4):999-1018.
PMID: 34996141
Numerous experimental DNA vaccines have been tested against , whose clinical use is mostly limited due to insufficient CD8 T cell-mediated immunity arising from poor gene delivery or presentation. Hence,...
3.
Asad M, Sabur A, Kamran M, Shadab M, Das S, Ali N
FASEB J
. 2021 Aug;
35(9):e21755.
PMID: 34383962
Visceral leishmaniasis (VL) is a debilitating human pathogenesis in which the body's immune functions are severely compromised. Various subsets of T cells, including Th17 cells are important regulators of immune...
4.
Didwania N, Ejazi S, Chhajer R, Sabur A, Mazumder S, Kamran M, et al.
J Clin Microbiol
. 2020 Aug;
58(11).
PMID: 32848039
Visceral leishmaniasis (VL) is a threat in many developing countries. Much effort has been put to eliminating this disease, for which serodiagnosis remains the mainstay for VL control programs. New...
5.
Asad M, Sabur A, Shadab M, Das S, Kamran M, Didwania N, et al.
Front Immunol
. 2019 Nov;
10:2409.
PMID: 31681298
[This corrects the article DOI: 10.3389/fimmu.2019.00616.].
6.
Asad M, Sabur A, Shadab M, Das S, Kamran M, Didwania N, et al.
Front Immunol
. 2019 Apr;
10:616.
PMID: 31031744
Immunosuppression is a characteristic feature of chronic leishmaniasis. The dynamicity and the functional cross talks of host immune responses during infection are still not clearly understood. Here we explored the...
7.
Ejazi S, Bhattacharyya A, Choudhury S, Ghosh S, Sabur A, Pandey K, et al.
Sci Rep
. 2018 Aug;
8(1):12110.
PMID: 30108316
Visceral leishmaniasis (VL), a potentially fatal disease is an outcome of infection caused by the parasite Leishmania donovani. The clinical diagnostic tests for this disease are still related to invasive...
8.
Sabur A, Bhowmick S, Chhajer R, Ejazi S, Didwania N, Asad M, et al.
Front Immunol
. 2018 Feb;
9:18.
PMID: 29441060
Despite advances, identification and formulation of safe and effective vaccine for long-lasting protection against leishmaniasis is still inadequate. In this study, we have identified a novel antigen, leishmanial elongation factor-1α...
9.
Didwania N, Shadab M, Sabur A, Ali N
Front Immunol
. 2018 Jan;
8:1779.
PMID: 29312309
Leishmaniasis is a neglected protozoan disease that mainly affects the tropical as well as subtropical countries of the world. The primary option to control the disease still relies on chemotherapy....
10.
Sabur A, Asad M, Ali N
Cell Immunol
. 2016 Jul;
309:55-60.
PMID: 27470274
Disease management of leishmaniasis is appalling due to lack of a human vaccine and the toxicity and resistance concerns with limited therapeutic drugs. The challenges in development of a safe...